In a large study of men with newly diagnosed diabetes, exposure to metformin in the previous year was associated with an increased risk for a prostate cancer diagnosis, whereas exposure 2 to 7 years previously was associated with decreased risk.
Researchers conducted a study to determine whether treatment with sotrovimab decreases the risk for severe disease progression among high-risk patients with mild-to-moderate COVID-19.
A network meta-analysis was done to compare the effectiveness of SGLT2 inhibitors in participants with type 2 diabetes and cardiovascular risk factors.
